Luna's gaseous emboli counter:
This article was originally published in Clinica
Luna Innovations has received US FDA 510(k) market clearance for its ultrasound-based technology for noninvasively counting and measuring gaseous emboli in real-time during cardiopulmonary bypass surgery, the EDAC (emboli detection and classification) quantifier. One of the most significant risks associated with emboli is brain damage caused by gaseous microemboli introduced into the cerebral blood flow during cardiopulmonary bypass procedures, said the Roanoke, Virginia firm. EDAC can provide surgeons with data on the quantity and volume of gaseous emboli at multiple locations in extracorporeal circuits during a procedure, enabling them to reduce the neurocognitive side-effect problems associated with cardiopulmonary bypass.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.